{"id":"306d4e50-582e-5227-bee5-2c42a21acccf","stable_key":"a9828b14-fbd7-57bf-9e01-0d52d1b42a1f:citrulline-pad-walking","predicate":"improved","statement":"Walking-distance change was 20.11% with citrulline versus 5.73% with placebo, P=0.011.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"1cf01c68-776e-5b0b-9fc5-7c8d8e5acc14","mechanism_event_label":"A patient-relevant walking endpoint improved in this preliminary PAD trial.","subject":{"id":"f53c7bfb-3b91-56fe-bebd-28623cfe13a0","slug":"citrulline","display_name":"L-Citrulline","entity_type_key":"small_molecule"},"object":{"id":"2a871f89-5912-5f76-9888-e726c298ffe6","slug":"absolute-claudication-distance","display_name":"Absolute claudication walking distance","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"1cf01c68-776e-5b0b-9fc5-7c8d8e5acc14","stable_key":"a9828b14-fbd7-57bf-9e01-0d52d1b42a1f:citrulline-pad-walking-event","event_type":"biochemical_relationship","label":"A patient-relevant walking endpoint improved in this preliminary PAD trial.","description":"Walking-distance change was 20.11% with citrulline versus 5.73% with placebo, P=0.011.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"f53c7bfb-3b91-56fe-bebd-28623cfe13a0","slug":"citrulline","display_name":"L-Citrulline","entity_type_key":"small_molecule"},"role":"intervention","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"1c231b90-c106-507a-8766-870ecb40e368","slug":"tetrahydrobiopterin","display_name":"Tetrahydrobiopterin / BH4","entity_type_key":"small_molecule"},"role":"additional_cofactor","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"6c8e2535-0002-5b29-bb3d-36cb341b85d2","slug":"asymmetric-dimethylarginine","display_name":"Asymmetric dimethylarginine / ADMA","entity_type_key":"small_molecule"},"role":"stratification_marker","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"2a871f89-5912-5f76-9888-e726c298ffe6","slug":"absolute-claudication-distance","display_name":"Absolute claudication walking distance","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/citrulline-research/39985883.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"0007fe7b3fcc746e77c450f3aca50ca2834c78b84aa83977b3078ae05051ab9c\", \"start_char\": 0, \"end_char\": 1888, \"text_sha256\": \"0007fe7b3fcc746e77c450f3aca50ca2834c78b84aa83977b3078ae05051ab9c\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Phase II double-blind placebo-controlled crossover trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"3 g citrulline twice daily for 12 weeks; additional BH4 0.45 g/day for two weeks in one arm","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Preliminary trial; subgroup-dependent BH4 result and study-specific ADMA cutoff require confirmation; not a general supplement prescription.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Citrulline research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"citrulline","display_name":"L-Citrulline","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Human, 51 peripheral-artery-disease patients","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"A patient-relevant walking endpoint improved in this preliminary PAD trial.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[citrulline-p39985883] Nutritional L-Citrulline and Tetrahydrobiopterin in Peripheral Artery Disease: A Phase II Randomized Trial (CIPER Study). (2025). https://pubmed.ncbi.nlm.nih.gov/39985883/ DOI: 10.1016/j.jacadv.2025.101590","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Absolute claudication distance and plasma biomarkers","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"b8697d92-b327-5a71-bf3b-7cc6749f0f35","evidence_kind":"source_excerpt","locator":"Lines 1204-1215","start_line":1204,"end_line":1215,"excerpt":"### citrulline-pad-walking\nWalking-distance change was 20.11% with citrulline versus 5.73% with placebo, P=0.011.\nCondition category: normal\nnutrient_topic: Citrulline research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: A patient-relevant walking endpoint improved in this preliminary PAD trial.\norganism: Human, 51 peripheral-artery-disease patients\ntissue_or_cell_type: Absolute claudication distance and plasma biomarkers\nexperimental_model: Phase II double-blind placebo-controlled crossover trial\nlimitations: Preliminary trial; subgroup-dependent BH4 result and study-specific ADMA cutoff require confirmation; not a general supplement prescription.\nexposure: 3 g citrulline twice daily for 12 weeks; additional BH4 0.45 g/day for two weeks in one arm\nevidence_span: {\"source_cache\": \"artifacts/citrulline-research/39985883.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"0007fe7b3fcc746e77c450f3aca50ca2834c78b84aa83977b3078ae05051ab9c\", \"start_char\": 0, \"end_char\": 1888, \"text_sha256\": \"0007fe7b3fcc746e77c450f3aca50ca2834c78b84aa83977b3078ae05051ab9c\"}\n[citrulline-p39985883] Nutritional L-Citrulline and Tetrahydrobiopterin in Peripheral Artery Disease: A Phase II Randomized Trial (CIPER Study). (2025). https://pubmed.ncbi.nlm.nih.gov/39985883/ DOI: 10.1016/j.jacadv.2025.101590","model_system":"Phase II double-blind placebo-controlled crossover trial","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [citrulline-p39985883] Nutritional L-Citrulline and Tetrahydrobiopterin in Peripheral Artery Disease: A Phase II Randomized Trial (CIPER Study). (2025). https://pubmed.ncbi.nlm.nih.gov/39985883/ DOI: 10.1016/j.jacadv.2025.101590","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"112fd375-aa2a-59d2-8afd-6b2849bb79ee","stable_key":"import-a9828b14-fbd7-57bf-9e01-0d52d1b42a1f","title":"Citrulline: arginine recycling, nitrogen disposal and nutrient connections (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"3720442dbabc28cacefd2145c7c97bfb937df26dca8527fde219ecd3735ed558","revision_id":"41ac8493-b004-59d7-99b3-8a3ca7163d3a","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}